

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A method for treating cancer in a subject, comprising:
 - (a) eliminating proliferating and mature suppressor cells in the subject;
 - (b) preactivating lymphocytes from the subject *ex vivo*; and
 - (c) injecting the preactivated lymphocytes into the subject, thereby treating the cancer.
2. (withdrawn) The method of claim 1, wherein the suppressor cells are eliminated in a specific way.
3. (withdrawn) The method of claim 1, wherein the suppressor cells are eliminated in a non-specific way.
4. (withdrawn) The method of claim 1, wherein the suppressor cells are eliminated by contacting the suppressor cells with antibodies selected from the group consisting of (a) antibodies specific for CD-8 positive suppressor cells, (b) antibodies specific for inducer-suppressor cells, (c) antibodies specific for transducer-suppressor cells, (d) antibodies specific for a subpopulation of radiosensitive suppressor cells, (e) antibodies specific for immunocompetent (pan)-T cells, (f) antibodies specific for (pan)-leukocytes, and (g) polyclonal/polyvalent antibodies or globulins directed against T-cells and thymocytes or lymphocytes.

5. (withdrawn) The method of claim 1, wherein the suppressor cells are eliminated by contacting the suppressor cells with antibodies selected from the group consisting of T cell-specific monoclonal antibodies and T cell-specific polyclonal antibodies.
6. (withdrawn) The method of claim 3, wherein the antibodies are selected from the group consisting of anti-CD8, anti-CD1, anti-CD3, anti-CD5, anti-CD2 and anti-pan T antibodies.
7. (original) The method of claim 1, wherein the suppressor cells are eliminated by contacting the suppressor cells with cyclophosphamide and monoclonal or polyclonal antibodies recognizing the suppressor cells.
8. (withdrawn) The method of claim 1, wherein the suppressor cells are eliminated by contacting the suppressor cells with cyclophosphamide and CD-3 or CD-8 positive T-cells.
9. (original) The method of claim 1, wherein the lymphocytes of the subject are preactivated by contacting the lymphocytes *ex vivo* with tumor cells of the subject.
10. (new) A method for treating cancer in a subject, comprising:
 - (a) eliminating proliferating and mature suppressor cells in the subject, comprising contacting the suppressor cells with a cytotoxic agent and monoclonal or polyclonal antibodies recognizing the suppressor cells;

- (b) preactivating lymphocytes from the subject *ex vivo*; and
- (c) injecting the preactivated lymphocytes into the subject, thereby treating the cancer.

11. (new) The method of claim 10, wherein the cytotoxic agent is cyclophosphamide.

12. (new) The method of claim 10, wherein the lymphocytes of the subject are preactivated by contacting the lymphocytes *ex vivo* with tumor cells of the subject.